Spring Bank Pharmaceuticals has formed a clinical trial collaboration with Gilead Sciences for a Hepatitis B (HBV) Phase 2 clinical study with Spring Bank's SB 9200 in combination with Viread (tenofovir disoproxil fumarate) for HBV patients.
Subscribe to our email newsletter
Spring Bank chief medical officer Nezam Afdhal said: "Although medications like Viread® are excellent at suppressing HBV replication, ‘HBV cure’ has remained elusive. We are very excited to move SB 9200 into Phase 2 clinical development in collaboration with Gilead.
"We believe that SB 9200 has the potential to be an important advance in the treatment of HBV patients, providing the potential for clearance of HBsAg, or functional cure, and will be studied both alone and in combination with Viread."